At a glance
ClinicalIndex Comparison Record- ✓Diagnosis of schizophrenia or schizoaffective disorder
- ✓Current smoking of 20–50 cigarettes per day
- ✓Clinically stable on antipsychotic and antidepressant medications
- ✕Pregnant or nursing women
- ✕Seizure disorder or lowered seizure threshold from other medical conditions
- ✕Positive urine drug screen or positive breath alcohol test
- ✕Use of MAO inhibitors within past 2 weeks
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Incentives Plus Bupropion for Smoking in Schizophrenics
In Brief
A Phase 2 clinical trial evaluating Bupropion, Contingent reinforcement plus placebo, and 2 other interventions for Schizophrenia and Disorders With Psychotic Features and Tobacco Use Disorder. Completed, enrolled 57 participants across 1 site.
Detailed Summary
There is a high prevalence of smoking among people with schizophrenia, and there are few smoking treatment programs for these smokers. The aims of this study are to investigate the separate and combined effects of bupropion and a voucher incentive program on smoking in people with schizophrenia.
Study Details
Timeline
Interventions
Contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
contingent reinforcement plus placebo (3 weeks)
non-contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
Non-contingent reinforcement plus placebo